



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/517,702

08/02/2005

Koji Sode

3691-0113PUS1

4690

2292

7590

04/14/2006

BIRCH STEWART KOLASCH & BIRCH

PO BOX 747

FALLS CHURCH, VA 22040-0747

EXAMINER

MEAH, MOHAMMAD Y

ART UNIT

PAPER NUMBER

1652

DATE MAILED: 04/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/517,702	Applicant(s) SODE, KOJI	
	Examiner Mohammad Meah	Art Unit 1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE _____ MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on _____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-30 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-30 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

The claims 1-30 are pending in the instant office action.

Restriction

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I claims 1-3, 14-~~16~~, 29-30, drawn to a modified glucose dehydrogenase wherein Met365 or Met365 and Asp167 in SEQ ID NO: 1 are replaced.

Group II claim(s) 1, 4-5, 14-17, 29-30, drawn to a modified glucose dehydrogenase wherein Thr366 or Thr366 and Asp167 in SEQ ID NO: 1 are replaced.

Group III claim(s) 1, 6-7, 14-16, 29-30, drawn to a modified glucose dehydrogenase wherein Tyr367 or Tyr367 and Asp167 in SEQ ID NO: 1 are replaced.

Art Unit: 1652

Group IV claim(s) 1, 8-9, 14-16, 29-30, 29-30, drawn to a modified glucose dehydrogenase wherein Ile368 or Ile368 and Asp167 in SEQ ID NO: 1 are replaced.

Group V claim(s) 1, 10-11, 14-16, 29-30, drawn to a modified glucose dehydrogenase wherein Cys369 or Cys369 and Asp167 in SEQ ID NO: 1 are replaced

Group VI claim(s) 1, 12-16, 29-30, drawn to a modified glucose dehydrogenase wherein Ala374 or Ala374 and Asp167 in SEQ ID NO: 1 are replaced.

Group VII claim 18, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 3.

Group VIII claim 19, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 4.

Group IX claim 20, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 5

Group X claim 21, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 6.

Group XI claim 22, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 7.

Group XII claim 23, drawn to a modified glucose dehydrogenase comprising SEQ ID NO: 8.

Art Unit: 1652

Group XIII claims 24-28, drawn to DNA, vector, transformant and methods of production of glucose dehydrogenase of claim 1.

The inventions listed as Groups I-XIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I-XII inventions do not share same technical features as proteins of Group I-XII, nucleotides, vector and host cell of group XIII are each unrelated and chemically distinct entities having technical feature different from that of other.

Furthermore; the technical feature linking group I- XIII appears to be that they all relate to glucose dehydrogenase . The protein, glucose dehydrogenase of claim 1 do not

constitute a "special technical feature" as defined by PCT Rule 13.2,

because it does not claim a feature, which defines a contribution over the prior art as

glucose dehydrogenase of claim 1 is taught by Yoshida et al. (Enz. and Micbiol Tec. 30 (2002) 312-318).

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).


Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah, PhD
Examiner, Art Unit 1652
Recombinant Enzymes, 3C31 Remsen Bld
400 Dulany Street, Alexandria, VA 22314
Telephone: 517-272-1261


REBECCA E. PROUTY
PRIMARY EXAMINER
GROUP 1800
1652